Long-term Study of Endoscopic Treatment of Stenosis in Crohn´s Disease

Long-term Follow-up ProtDilat Study; Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease: Self-expandable Metal Stent vs. Endoscopic Balloon Dilatation

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06036680

Acronym

Long-ProtDilat

Enrollment

Registered

2023-09-14

Start date

2022-12-19

Completion date

2023-12-31

Last updated

2023-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Stenosis

Keywords

endoscopic balloon dilatation, self-expanding metal stent

Brief summary

Stenosis is one of the most frequent complications in patients with Crohn's disease (CD), causing greater morbidity and increasing the probability of repeated surgery and short bowel syndrome. Several endoscopic techniques, as an alternative to surgery, have been used in the treatment of fibrostenotic CD, with similar efficacy and lower risk of complications. The ProtDilat study (NCT02395354) showed that both endoscopic balloon dilation (EBD) and self-expandable metal stents (SEMS) are efficient and safe for the treatment of stenosis in CD, while EBD shows therapeutic superiority (80.5 vs 51.3 %) at one year follow-up. However, this difference was not observed in the subanalysis of patients with stenosis \> 3 cm (EBD: 66.7% vs SEMS: 63.6%) but with a lower cost for EBD (EDB 1,365.63 euros versus SEMS 1,923.55 euros). Therefore, SEMS could be a suitable treatment option for longer stenoses in which EBD has proven to be less efficacious. Moreover, the long-term efficacy of both endoscopic treatments is still debated with scare information and without data from a clinical trial. The aim of this study is to assess the long-term efficacy of EBD and SEMS, through the follow-up of the patients included in the ProtDilat study, being the primary objective of the study the percentage of patients free of surgical intervention at the end of follow-up. Retrospective study based on data from the ProtDilat trial (patients with CD, obstructive symptoms, with stenosis \< 10cm). Data on medical, endoscopic and surgical treatment and smoking habits are collected.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

* Age18-75. * CD with predominating de novo and/or anastomotic fibrotic stenosis confirmed by endoscopy and radiology and accessible by endoscopy (colonoscopy). * Stenosis previously treated with a stent and/or dilatation and with at least one year asymptomatic. * Intestinal occlusion or sub-occlusion symptomatology. * Refractoriness to conventional medical treatment (no response to accelerated step-up of normal therapeutic scale). * Stenosis length \< 10 cm. * Maximum 2 stenoses. * Informed consent of patient.

Exclusion criteria

* No informed consent of patient. * Stenosis complicated by abscess, fistula, or important activity associated with CD not limited to the stenosis area. * Stenosis previously treated with a stent and/or dilatation and with less than one year asymptomatic. * Pregnancy or lactation. * Any clinical condition that prevents the performance of endoscopy. * Stenosis inaccessible by colonoscopy. * No obstructive symptoms. * Stenosis length ≥ 10 cm. * Presenting more than 2 stenoses. * Serious coagulation disorder (platelets \< 70000; INR \> 1.5)

Design outcomes

Primary

Measure	Time frame
Percentage of surgery-free patients post-treatment	end of long-term follow up (median 7 years post-treatment)

Secondary

Measure	Time frame
Percentage of patients that have not required any endoscopic retreatment	end of long-term follow up (median 7 years post-treatment)
Long-term effectiveness of endoscopic treatment (SEMS vs EBD): percentage of patients free of surgery and who have not required any endoscopic retreatment	end of long-term follow up (median 7 years post-treatment)
Percentage of patients with safety issues and/or complications related to endoscopic or surgical treatment	end of long-term follow up (median 7 years post-treatment)

Countries

Spain

Outcome results